Loading...

Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144824/
https://ncbi.nlm.nih.gov/pubmed/24869598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1400029
Tags: Add Tag
No Tags, Be the first to tag this record!